YIH
PMVP icon

Y-Intercept (HK)’s PMV Pharmaceuticals PMVP Stock Holding History

Y-Intercept (HK)’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,749
Closed -$51.4K – 1695
2024
Q2 		$51.4K Buy
+31,749
New +$57.3K ﹤0.01% 1302
2023
Q2 		– Sell
-33,272
Closed -$159K – 1624
2023
Q1 		$159K Buy
+33,272
New +$234K 0.02% 1005

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Y-Intercept (HK)'s PMVP Position: Q3 2024 in Review

Y-Intercept (HK) sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 31,749 shares — an estimated $51.4K sold.

Y-Intercept (HK) first reported a position in PMVP in Q1 2023 and held it in 2 quarters. The position peaked at $159K in Q1 2023. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • Y-Intercept (HK) reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 31,749 PMV Pharmaceuticals shares in Q3 2024, an estimated $51.4K.
  • Y-Intercept (HK) first reported a position in PMV Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s PMV Pharmaceuticals position peaked at $159K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.